Seroefficacy of a 10-valent pneumococcal conjugate vaccine (Pneumosil®) compared with other pneumococcal conjugate vaccines in children.

VaccineAug 12, 2026 (epub)
Clinical ResearchPediatricsInfectious Diseases

Oluwasefunmi Akeju, Shuo Feng, Ed Clarke et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the seroefficacy of the 10-valent pneumococcal conjugate vaccine (PCV10 SII) in 716 infants compared to PCV10 GSK and PCV13. PCV10 SII showed a 65% lower risk of seroinfection for serotype 14 compared to PCV13, while providing better protection against serotypes 6A and 19A, which are not included in PCV10 GSK.

Key findings

  • PCV10 SII had a 65% lower risk of seroinfection for serotype 14 compared to PCV13 (RR = 0.35).
  • PCV10 SII showed 2.27-fold higher risk for seroinfection of serotype 6A compared to PCV13.
  • PCV10 SII demonstrated better protection against serotypes 6A and 19A not included in PCV10 GSK.
  • No difference in risk of seroinfection was found between PCV10 SII and PCV10 GSK for shared serotypes.

Why it matters

Understanding the comparative efficacy of pneumococcal vaccines is crucial for guiding immunization strategies, especially in regions with high prevalence of specific serotypes. This study highlights the potential advantages of PCV10 SII in providing broader protection.

Source

PubMed · PMID 42585812

Published in Vaccine. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.